Hepatitis B
National Hepatitis Testing Day: Most Infected Are Unaware, All Boomers Should Get HCV Test
- Details
- Category: HBV Testing & Diagnosis
- Published on Friday, 18 May 2012 00:00
- Written by Liz Highleyman
In advance of the National Hepatitis Testing Day on Saturday, May 19, the U.S. Centers for Disease Control and Prevention (CDC) has issued a new recommendation that all Baby Boomers born between 1945 and 1965 should get tested at least once for hepatitis C. Testing Day events will also promote hepatitis B screening, especially for Asian communities. Research shows that a large majority of people with hepatitis B or C do not know they are infected.
EASL: Telbivudine Effective for Hepatitis B Patients Selected with Roadmap
- Details
- Category: HBV Treatment
- Published on Tuesday, 08 May 2012 00:00
- Written by Liz Highleyman
Telbivudine (Tyzeka) is an effective treatment for chronic hepatitis B with minimal emergence of drug resistance when using the "Roadmap" algorithm for selecting appropriate patients and deciding when to add other agents, according to a trio of studies presented at the 47th International Liver Congress (EASL 2012) last month in Barcelona.
Complete Coverage of the 2012 International Liver Congress
- Details
- Category: HBV Treatment
- Published on Wednesday, 25 April 2012 00:00
- Written by Liz Highleyman
HIVandHepatitis.com coverage of the 2012 International Liver Congress -- 47th Annual Meeting of the European Association for the Study of the Liver (EASL), April 18-22.
Conference highlights include experimental hepatitis C therapies, interferon-free regimens, boceprevir (Victrelis) and telaprevir (Incivek/Incivo) in real-world practice, difficult-to-treat patients, HIV/HCV coinfection, hepatitis B research, and liver cancer research.
HIVandHepatitis.com EASL 2012 conference section
EASL: Having Only Wild-type Hepatitis B Virus Predicts Response to Interferon
- Details
- Category: HBV Treatment
- Published on Friday, 04 May 2012 00:00
- Written by Liz Highleyman
Chronic hepatitis B patients who do not have 2 common HBV mutations are more likely to achieve undetectable viral load and HBsAg loss when treated with pegylated interferon, according to study findings presented at the 47th International Liver Congress (EASL 2012) last month in Barcelona.
EASL: Entecavir (Baraclude) Prevents Hepatitis B Recurrence after Liver Transplant
- Details
- Category: HBV Treatment
- Published on Tuesday, 24 April 2012 00:00
- Written by Liz Highleyman
No patients treated with entecavir (Baraclude) after receiving liver transplants due to complications of chronic hepatitis B experienced virological recurrence, according to a study described at the 47th International Liver Congress (EASL 2012) last week in Barcelona.
May Is Hepatitis Awareness Month
- Details
- Category: Hepatitis B
- Published on Wednesday, 02 May 2012 00:00
- Written by Liz Highleyman
May is designated as Hepatitis Awareness Month in the U.S., an opportunity to promote better understanding of and encourage testing and care for viral hepatitis.
EASL: Entecavir plus Tenofovir for Hepatitis B Patients with Prior Treatment Failure
- Details
- Category: HBV Treatment
- Published on Friday, 20 April 2012 00:00
- Written by Liz Highleyman
A combination of entecavir (Baraclude) plus tenofovir (Viread) resulted in hepatitis B virus (HBV) suppression in a majority of patients who previously experienced treatment failure, according to a study presented at the 47th Annual Meeting of the European Association for the Study of the Liver (EASL 2012) this week in Barcelona.
EASL: Brivanib Did Not Improve Overall Liver Cancer Survival, but Did Show Anti-tumor Activity
- Details
- Category: Liver Cancer/HCC
- Published on Friday, 27 April 2012 00:00
- Written by Liz Highleyman
The experimental cancer drug brivanib did not lengthen overall survival for patients with hepatocellular carcinoma, but it did increase time to progression, demonstrating that it had anti-tumor activity, researchers reported at the 47th International Liver Congress (EASL 2012) last week in Barcelona.
EASL International Liver Congress Starts This Week in Barcelona
- Details
- Category: HBV Treatment
- Published on Tuesday, 17 April 2012 00:00
- Written by Liz Highleyman
The 47th Annual Meeting of the European Association for the Study of the Liver (EASL 2012) takes place this week, April 18-22, in Barcelona. HIVandHepatitis.com will be on site to provide breaking news and analysis.
More Articles...
- Androgens Promote Hepatitis B Virus Replication, Helping Explain Sex Differences
- Statins May Reduce Liver Cancer Risk among People with Hepatitis B
- High HBV Viral Load Linked to Greater Risk of Liver Cancer
- Hepatitis B and C Are Major Causes of Liver Cancer in U.S.
- MicroRNA Blood Test May Help Diagnose Early Liver Cancer in People with Hepatitis B
